SCHEMBL15078466

SCHEMBL15078466

CCC(OC(N)=O)C(OCOC)c1c(Cl)cccc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
TAS1R2 Q8TE23 1/20 0.32
CYP2C9 P11712 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C19 P33261 2/20 0.31
KMT2A Q03164 2/20 0.31
HIF1A Q16665 2/20 0.31
HSD17B10 Q99714 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
TP53 P04637 1/20 0.31
CYP2D6 P10635 1/20 0.31
TSHR P16473 1/20 0.31
NFKB1 P19838 1/20 0.31
THPO P40225 1/20 0.31
NR1I2 O75469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15078403 1.00 TAS1R3 (0.32) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078454 1.00 TAS1R3 (0.32) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078471 0.88 MEN1 (0.32) TAS1R3TAS1R1KDM4EMEN1KMT2A
SCHEMBL15078459 0.88 MEN1 (0.32) TAS1R3TAS1R1KDM4EMEN1KMT2A
SCHEMBL15078408 0.88 MEN1 (0.32) TAS1R3TAS1R1KDM4EMEN1KMT2A
SCHEMBL15078565 0.87 TAS1R3 (0.35) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078515 0.87 TAS1R3 (0.35) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078556 0.87 TAS1R3 (0.35) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078590 0.86 TAS1R3 (0.36) TAS1R3TAS1R1TAS1R2CYP2C9KDM4E
SCHEMBL15078371 0.86 CASP1 (0.37) KMT2AALDH1A1HPGDLMNAAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2013100566-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 TAS1R3 3564/4885TAS1R1 3983/4885TAS1R2 3880/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 TAS1R3 3708/4885TAS1R1 3765/4885TAS1R2 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.